Impaired blood vessel and kidney function underlie heart disease risk in people with HIV

Research Highlights:

  • People living with human immunodeficiency virus (HIV) have impaired blood vessel function, which increases risk of heart and blood vessel-disease.
  • The increased heart disease risk is especially pronounced in people with HIV who also have kidney disease.
  • The increased heart disease risk remains regardless of HIV severity or use of antiretroviral therapy.
  • People living with HIV, especially those with kidney disease, should reduce heart disease risk factors such as high blood pressure.

Embargoed until 4 a.m. CT/5 a.m. ET Thursday, Dec. 17, 2020                                                                                                                   

DALLAS, Dec. 17, 2020 — People living with human immunodeficiency virus (HIV) have impaired blood vessel function, which increases cardiovascular disease risk, according to new research published today in the American Heart Association’s journal Arteriosclerosis, Thrombosis and Vascular Biology (ATVB). The connection between impaired blood vessel function and cardiovascular disease was especially strong among people with HIV and kidney disease.

Cardiovascular disease is the leading cause of death among people living with HIV, however, the reasons for the strong association have not been clear. This study shows a correlation between HIV and impaired blood vessels, even when HIV is well-controlled.

“People living with HIV infection need to be vigilant about heart disease prevention. They cannot assume that their heart and blood vessel disease risk is low because their infection is controlled,” said study author James H. Stein, M.D., the Robert Turell Professor in Cardiovascular Research at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin.

Stein and colleagues measured brachial artery flow-mediated dilation, a measure of endothelial function, in participants from 9 studies. The studies included 986 adults living with HIV and 1,547 who did not have the virus.

The analysis revealed:

  • People living with HIV infection had about 1% lower flow-mediated dilation (indicating impaired blood vessel function) compared to people without HIV. To put this finding in perspective, a 1% lower flow-mediated dilation is associated with a 10% to 11% increased future cardiovascular disease risk for middle- and older-aged adults.
  • HIV disease severity and use of antiretroviral therapy did not notably influence risk of impaired blood vessel function.
  • Higher levels of creatinine in the blood, a marker of reduced kidney function, was related to lower blood vessel function among those who were HIV positive.
  • Kidney function had a greater connection to blood vessel function in people with HIV than in people without HIV infection.

Researchers were surprised that patients’ control of HIV infection did not appear to have an impact on endothelial function. “The finding that HIV positive status was associated with impaired endothelial function suggests that HIV infection might increase cardiovascular disease risk beyond normal risk factors like cholesterol levels or high blood pressure,” said Stein.

“We also did not expect such a large effect from kidney function on HIV patients’ endothelial health,” said Stein. “Even mild kidney disease might play a role in HIV-associated cardiovascular disease risk.”

Researchers measured blood vessel function and not heart attacks, which could be a study limitation, noted Stein. “The test we used quantifies blood vessel dysfunction that could predict bad outcomes, but the results are not a bad outcome on their own.”

“Regardless,” he said, “people can protect their kidneys and prevent cardiovascular disease by doing such things as controlling blood pressure and preventing diabetes.”

Co-authors are Noah Kime, B.S.; Claudia E. Korcarz, D.V.M.; Heather Ribaudo, Ph.D.; Judith S. Currier, M.D., M.P.H.; and Joseph C. Delaney, Ph.D. Author disclosures are in the manuscript.

This study was funded by The National Heart, Lung, and Blood Institute of the National Institutes of Health. The National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, and the National Cancer Institute of the National Institutes of Health funded the studies that provided the health information used for the analyses in this study.

Additional Resources:

Statements and conclusions of studies published in the American Heart Association’s scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

###

For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173

Maggie Francis: maggie.francis@heart.org; 214-706-1382

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org

AHA Logo
This link is provided for convenience only and is not an endorsement of either the linked-to entity or any product or service.
CLOSE PROCEED